PCSK9 Levels and Metabolic Profiles in Elderly Subjects with Different Glucose Tolerance under Statin Therapy.

Kari A MäkeläJari JokelainenVille StenbäckJuha AuvinenMarjo-Riitta JärvelinMikko TulppoJuhani LeppäluotoSirkka Keinänen-KiukaanniemiKarl-Heinz Herzig

Published in: Journal of clinical medicine (2021)

our data suggest that in subjects with abnormal glucose metabolism and statin therapy, the significant PCSK9-mediated effects on the lipid metabolites are lost com-pared to NGT subjects, but statins reduced the LDL-C and VLDL-C levels.

Keyphrases

low density lipoprotein
cardiovascular disease
coronary artery disease
ms ms
electronic health record
middle aged
type diabetes
stem cells
fatty acid
artificial intelligence